Sector News

CEO of Novo Nordisk's biggest shareholder steps down

February 15, 2016
Life sciences

(Reuters) – Novo A/S, the parent company behind the world’s largest insulin maker Novo Nordisk said on Friday Chief Executive Eivind Kolding will step down at the end of the month.

Kolding, 56, has previously served as chief executive of Denmark’s largest bank, Danske Bank, and the world’s largest container shipping company, Maersk Line. He has been in the Novo job less than two years.

Aside from its shares in Novo Nordisk and top industrial enzyme maker Novozymes, Novo A/S has billions invested in both Danish and international life science companies.

“The board has concluded that having a CEO with a different profile to that of Eivind Kolding will be required in the long term,” chairman of the board Steen Scheibye said.

Novo said the hunt for a replacement has begun, but gave no further details. Scheibye becomes acting chief executive when Kolding leaves. ($1 = 6.6383 Danish crowns) (Reporting by Annabella Pultz Nielsen; Editing by Greg Mahlich)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).